Aurinia Announces Results of the 2021 Annual General Meeting
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP)
(“Aurinia” or the “Company”) is pleased to announce
that the eight incumbent directors of the Company were elected at
the Company’s annual general meeting (the “Meeting”) held on
June 7, 2021.
Detailed results of the vote by
proxy for the election of directors are provided below:
Votes For (%)
Votes Withheld (%)
In addition, following final tallies of votes, all other matters
voted on at the Meeting were also approved. Voting results
on all matters voted on at the Meeting will be filed on SEDAR at
www.sedar.com and EDGAR at www.edgar.com.
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to treat targeted patient
populations that are impacted by serious diseases with a high unmet
medical need. The Company’s head office is in Victoria, British
Columbia, its U.S. commercial hub is in Rockville, Maryland, and
the Company focuses its development efforts globally.
version on businesswire.com: https://www.businesswire.com/news/home/20210607005782/en/
Investors: Glenn Schulman, PharmD, MPH Investor Relations
& Corporate Communications, Aurinia email@example.com
Media: Dana Lynch Corporate Communications, Aurinia